The Use of PARP Inhibitors in Ovarian Cancer

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).